FDA Approves 3MP X-ray Display for Mammography…

E-mail Print PDF
A 21.3-inch display with a brightness of 1,700 cd/m˛ and contrast of 1400:1 is tailored for all conventional X-ray applications and examinations of the thorax. Furthermore, the display supports independent subpixel driving (ISD), which raises the resolution by three.  “This is the reason for the mammography approval from the US Food and Drug Administration [FDA],” explained marketing manager, medical displays at Totoku, Marcel Herrmann. With the new grayscale display MS35i2 , Totoku (Tokyo, Japan) extends his range of light-emitting diode (LED) products with a 3 megapixel (MP) display. The MS35i2 also comes with the new LED backlight. The heir of the cold cathode fluorescent lamp (CCFL) technology is based on semiconductors.  “The benefits are both ecological as well as financial and qualitative nature. Compared to CCFL monitors, LED displays, save up to 20% electricity and have a longer life span by approximately30%. This has a positive effect on the budget of the user. Furthermore, the CO2 emissions decrease due to reduced energy production. Specifically, the MS35i2 display will use 15% less power than its predecessor, at the same time almost doubles the lifetime, and disposal is much more environmentally friendly, since LEDs do not contain critical elements such as mercury,” commented Herrmann. While the CCFL was positioned horizontally behind the display, the LED offers a considerably higher number of light sources. Because of this, they can be individually managed and controlled, resulting in an optimized consistency. All new i2 models feature the new display port interface. This allows the user to connect not only to DVI signals or video cards, but also with the most recent display port cards from numerous vendors, for instance Matrox, ATI, and NVIDIA.  Another advantage from display port is the enhanced greyscale duplication. For the very first time the display port offers true 10-bit grayscales on a color display and true 11-bit for the grayscale ... Read more

Survival Improvement in Pulmonary Fibrosis Possible …

E-mail Print PDF
Researchers from the University of Illinois at Chicago College of Medicine have recently discovered a protein molecule that appears to slow the development of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years ... Read more

Software Platform Desgined for Managing, Utilizing, …

E-mail Print PDF
A recent update of an oncology software platform equips physicians with a wide range of new tools that render the use of diverse types of images so much easier and automates time-consuming image-processing tasks that are critical to treating cancer with image-guided radiotherapy or radiosurgery. Velocity software is designed to find a point of entry and amass unstructured treatment and imaging data from varied systems to demonstrate a broad view of a patient’s diagnostic imaging and treatment history, regardless of where they were treated or what technology was applied. The software allows clinicians to utilize oncology patient images and data to plan and assess treatment options, work in partnership with colleagues, and share clinical knowledge. By sorting out and systematizing patient data and making it accessible in one designated area, the Velocity software can aid healthcare professionals in making better, more knowledge based treatment decisions. This newest Velocity software release also adds an array of new applications that make it simpler to merge images, measure and determine the probable impact of different doses of radiation on tumors, and normal tissues, automate several intricate image handling processes, and effectively utilize the program to communicate and cooperate with other with colleagues. Varian Medical Systems (Palo Alto, CA, USA) acquired the Velocity software platform from a privately-held Atlanta, GA, USA, firm in April 2014.  “We’re very pleased with how the integration process is going, and looking forward to sharing this latest Velocity release with Varian customers and others interested in our growing collection of tools for data-driven clinical decision making. The Velocity software product will be among the products highlighted within the Varian booth at the upcoming annual meetings of the American Association of Medical Dosimetrists [AAMD] and the American Association of Physicists in Medicine [AAPM] later this year," said associate vice president, imaging informatics at Varian, Tim ... Read more

New Imaging Technology Could Lead to Greater Precision …

E-mail Print PDF
A novel imaging techonolgy, referred to as phase contrast x-ray imaging has allowed researchers from TH Zurich, the Paul Scherrer Institute (PSI) and the Kantonsspital Baden to conduct mammographic imaging that leads to higher accuracy in the ... Read more

Hyperfractionated RT May Benefit Patients with Locally …

E-mail Print PDF
Based on a recent study published in the May edition of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO), patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) noted improved local-regional control and over a five year lapse experienced improved overall survival with no spike in toxicity. The study which is called, "Final Results of Local-Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer," includes several institutional randomized Phase III trial of fractionation in locally advanced head and neck cancer. The study, which is considered the largest fractionation study conducted at this point, assessed patients who were treated with standard fractionation (SFX) as opposed to those who received HFX, accelerated fractionation with a split (AFX-S) or accelerated fractionation-continuous (AFX-C). Patients registered in the study were age 18 years or older and had previously untreated, locally advanced squamous cell cancers of the oral cavity, oropharynx or supraglottic larynx in stage III or IV or stage II-IV carcinoma of the base of the tongue or hypopharynx. Patients with a prior (within five years) or synchronous malignancy other than nonmelanoma skin cancer were exempted from the trial. The trail amassed a total of 1,076 patients from September 30, 1991 to August 1, 1997. Patients were randomized to four different treatment strategies: SFX (2 Gy/fraction/day to 70 Gy in 35 fractions over seven weeks), HFX (1.2 Gy/fraction, twice daily, to 81.6 Gy over seven weeks), AFX-S (1.6 Gy/fraction, twice daily, to 67.2 Gy over six weeks, with a two-week break after 38.4 Gy) and AFX-C (total dose of 72 Gy delivered over six weeks in 1.8 Gy daily fractions and additional 1.5 Gy boost field in the afternoon during the last 12 days of treatment). All treatments were delivered five days a week, and twice-daily treatments had a minimum interfraction interval of six hours. Local-regional failure was examined at two years, at five years and at last follow-up. As of October 1, 2012, the average follow-up was 14.1 years. Toxicity and disease recurrence evaluation was performed weekly while patients underwent RT; four months following treatment completion; every three months for one-and-a-half years; every four months between one-and-a-half and three years; every six months in years three to five; and then annually until death. Toxicities that took place less than180 days from the beginning of radiation were classified as acute, and those occurring more than180 days following RT were considered late effects. At the time of this report's analysis in October 2012, 52.7 percent of patients (568) had experienced local-regional failure, with 97.4 percent (553) happening within the first five years. Secondary primary cancers were reported for 18.6 percent of patients (200), with 50 percent (100) reported within the first three years, and 75 percent (150) reported within the first 5.5 years. After 5.5 years following treatment, the rates of secondary malignancies decreased to less than 1 percent per year. There were no notable differences in the rates of second malignancies among all four study treatment plans. At five years, the occurrence of grade 3, 4 or 5 toxicity, any feeding tube use following 180 days or feeding tube use at one year did not differ considerably when the SFX arm was juxtaposed to the three experimental arms. Grade 3, 4 or 5 toxicity tended to be decreased for patients treated over seven weeks as opposed to those treated over six weeks (9.0 percent vs. 16.7 percent, respectively), and 4.8 percent of disease-free patients treated with HFX had feeding tubes compared to 13.0 percent of patients treated with AFX-C. At five-years after treatment, patients in the HFX arm had the highest overall survival rates at 37.1 percent (HR 0.81, 95 percent CI), as opposed to 33.7 percent for the AFX-C arm, 29.3 percent for the SFX arm, and 29.0 percent for the AFX-S arm. "This study, one of only a few large studies to have follow-up beyond five years, demonstrates that patients who have head and neck cancers and who are being treated with radiation therapy alone have improved local-regional control and no increase in late toxicity when radiation therapy is delivered twice a day in two smaller doses which we call hyperfractionation," said lead author of the study and professor of radiation oncology, otolaryngology and hematology/medical oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta, Jonathan J. Beitler, MD, MBA, FASTRO. "The decrease in the rate of new cancers was unexpected; however, the large database and the long follow-up provided us with a window into information that had not previously been available about the long-term patterns of head and neck tumors and is particularly heartening. The results suggest that twice-daily radiation may improve cure and limit late side effects for patients. Twice-daily radiation might be worth considering in place of concurrent chemoradiotherapy for those patients who are at low risk for distant metastases and those patients who cannot tolerate systemic ... Read more

Overestimation of Radiation Exposure Causes Women to …

E-mail Print PDF
According to a recent study, misconceptions and misinformation regarding the risks connected with ionizing radiation have led to a heightened public concern and fear, the outcome of which may lead to avoiding mammography screenings that can detect ... Read more

Drug Has Potential to Improve Effectiveness of …

E-mail Print PDF
According to a recent study, since there has been a growing interest in utilizing the body's own immune system to combat tumor cells, a method that has the possibility of being very effective without the side effects typically caused by standard ... Read more

Children Exposed to Unnecessary Radiation Following …

E-mail Print PDF
According to a new study from Utah, children with supposed sports-related head injuries discovered that emergency room visits have significantly increased since the state passed a concussion law back in 2011. Additionally an increase in CT scans, ... Read more

Iterative Reconstruction Methods Reduce Radiation Dose …

E-mail Print PDF
A study carried out by the Massachusetts General Hospital and Harvard Medical School found that estimated radiation doses are significantly lower for pediatric CT exams of the brain that employ an adaptive statistical iterative reconstruction technique (ASIR) as opposed to those that did not employ ASIR. Additionally, the researchers discovered that the brain and salivary gland doses were considerably lower for ASIR-enabled exams as opposed to those without ASIR technique. However, no differences in the estimated organ doses were discovered for the thyroid gland, skeleton, and eye lenses across the two groups of CT exams. "CT radiation dose is an important concern with all imaging sites, especially for children. We performed this study to do a preliminary analysis of pediatric head CT examinations and to assess the factors influencing radiation doses," said Ranish Deedar Ali Khawaja.  Average radiation dose was set at 1.6 ± 1.5 mSv (estimated effective dose) in pediatric head CT. Furthermore, to the iterative reconstruction algorithm, patient age and effective body diameter notably carried enough weight to impact the doses. Khawaja and his fellow researchers presented their study at the 2014 ARRS Annual Meeting in San Diego, ... Read more

Page 3 of 379

These signals are relayed buying clomid online safe which then is by a number of such as medial preoptic and paraventricular nulcei.